Is retatrutide FDA approved?
Retatrutide gets a lot of attention because of its trial results, so it is a common surprise that it cannot yet be prescribed. Here is exactly where it stands, why approval takes this long, and what the realistic timeline looks like.
On this page
Is retatrutide approved right now?
No. In August 2026, retatrutide is not an approved medicine anywhere. It has not been cleared by the FDA in the United States or by the EMA in the European Union. Any retatrutide available today is either supplied for research use or accessed through routes that sit outside an approved prescription.
What stage is retatrutide at?
Retatrutide is in Phase 3, the final and largest stage of human testing before a company applies for approval. Eli Lilly runs this under a programme called TRIUMPH, a set of large trials in different groups, including general obesity, obesity with type 2 diabetes, and obesity with heart disease. Through 2025 and 2026 several of these trials reported results, with average weight reductions in controlled settings in the range of roughly 20 to 29 percent depending on the group and length of the study.
Trial figures are an educational summary of published research and are not a claim about any outcome for any person.
Why is retatrutide not approved yet?
New medicines move through three phases of human trials. Phase 1 checks basic safety in a small group, Phase 2 tests whether it works and finds a dose range, and Phase 3 confirms both in thousands of people over a longer period. Only after Phase 3 does a company submit its full data to a regulator, who then reviews it before deciding. Each step takes time by design, because the goal is to catch rare or long-term problems before a drug reaches the public.
What does research use only mean?
When a compound is labelled for research use only, it means the trials a regulator needs are not complete, so there is no approved medical use. It is not a statement that the molecule is unsafe or low quality. It is a legal and regulatory status, not a quality grade. Material supplied for research is not tested or approved for human use, and honest suppliers say so plainly.
When could retatrutide be approved?
Based on the trial timeline, Eli Lilly is widely expected to file for approval around early 2027. A standard regulatory review then takes several months to about a year, so the earliest realistic approval window discussed publicly is late 2027 into 2028. Timelines can move, and an approval in one region does not automatically mean approval in another. For how retatrutide compares with drugs that are already approved, see retatrutide vs tirzepatide and retatrutide vs semaglutide.
References
- Retatrutide (LY3437943) Phase 3 TRIUMPH program. ClinicalTrials.gov. Trial records.
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315.
Frequently asked questions
Is retatrutide FDA approved in 2026?
No. As of August 2026 it is investigational and in Phase 3 trials. It is not approved by the FDA.
Is retatrutide approved in Europe?
No. The European Medicines Agency has not approved retatrutide. It has the same investigational status in the EU as in the United States.
When will retatrutide be approved?
A filing for approval is widely expected around early 2027, which would put a possible decision in 2027 or 2028. Dates can change.
Can you buy retatrutide legally?
It is not available as an approved prescription medicine. It is sold for research use only, which is not tested or approved for human use.